NDAORALTABLET
Approved
Mar 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
8
Data completeness
5/8 — Partial
TRYVIO (aprocitentan) by Idorsia is endothelin receptor antagonists [moa]. Approved for endothelin receptor antagonist [epc]. First approved in 2024.
Drug data last refreshed 19h ago
Mechanism of Action
Endothelin Receptor Antagonists
Pharmacologic Class:
Endothelin Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (8)
A Drug-drug Interaction Trial in Healthy Female Participants to Investigate the Effect of Aprocitentan on Combined Hormonal Contraceptives
Started Jan 2025
19 enrolled
Drug Drug Interaction
Bioequivalence Study of Different Aprocitentan Tablet Formulations
Started Feb 2022
36 enrolled
Healthy Subjects
The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics
Started Jun 2020
17 enrolled
Hepatic ImpairmentHealthy Subjects
To Study the Effect of Aprocitentan on the Electrical Activity of the Heart in Healthy Men and Women
Started Jan 2020
48 enrolled
Healthy Subjects
A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease.
Started Jan 2020
0HypertensionRenal Insufficiency, Chronic
Worked on TRYVIO at Idorsia? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.